Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents - C Macchi, M Banach, A Corsini, CR Sirtori, N Ferri, M Ruscica, 2019
Neue Therapieoptionen zur Lipidkontrolle // New therapy options for lipid control
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9 | SpringerLink
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Pharmaceutics | Free Full-Text | Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Small interfering ribonucleic acid for cholesterol lowering – Inclisiran: Inclisiran for cholesterol lowering - ScienceDirect
Therapeutic siRNA: state of the art | Signal Transduction and Targeted Therapy
2021 Peptides and Oligonucleotides Harvest | Encyclopedia MDPI
Leqvio - 5333 - EPAR
Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease | Cardiovascular Diabetology | Full Text
The current registered clinical studies on inclisiran (* recruiting... | Download Scientific Diagram
Donovan/Green
Inclisiran: A New Pharmacological Approach for Hypercholesterolemia
Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation | ACS Omega
Cureus | Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists | Article
The novel siRNA inclisiran and population health management - Walker - 2023 - Prescriber - Wiley Online Library
![PDF] Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1f1a62bb4b78002fe02ac9051fa4b11c68450b83/9-Figure2-1.png "PDF] Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol | Semantic Scholar")
PDF] Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol | Semantic Scholar
Dossier zur Nutzenbewertung gemäß § 35a SGB V
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia | NEJM
Diseases | Free Full-Text | Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
Advances in oligonucleotide drug delivery | Nature Reviews Drug Discovery
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 | NEJM
The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and effi
Dossier zur Nutzenbewertung gemäß § 35a SGB V
Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease | Cardiovascular Diabetology | Full Text
IJMS | Free Full-Text | Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia
